France· FR:66170619
IDEFIRIX 11 mg, poudre pour solution à diluer pour perfusion
A imlifidase product containing imlifidase, registered in France by HANSA BIOPHARMA (SUEDE). The same ATC class is registered in 12 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Imlifidase is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AA41 (imlifidase), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Imlifidase · ATC L04AA41
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of imlifidase costs, country by country.
Normalised to the WHO defined daily dose (17.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Imlifidase · price per daily dose (17.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$271803.14
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- IMLIFIDASE
- Manufacturer
- HANSA BIOPHARMA (SUEDE)
- Country
- France (FR)
- ATC code
- L04AA41
- ATC class
- Imlifidase
- Defined daily dose
- 17.5 mg, P
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip1334009550823541 flacon(s) en verre
- cip1334009550823612 flacon(s) en verre
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Imlifidase in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsIdefirix 11 mg, poeder voor concentraat voor oplossing voor infusieHansa Biopharma AB
- CzechiaIDEFIRIXHansa Biopharma AB, Lund
- SwitzerlandIdefirix
- FinlandIdefirixHansa Biopharma AB
- United KingdomIdefirix 11mg powder for concentrate for solution for infusion vialsHansa Biopharma AB
- IrelandIdefirix 11 mg powder for concentrate for solution for infusionHansa Biopharma AB
- IcelandIdefirixHansa Biopharma AB
- NorwayIdefirixHansa Biopharma AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Idefirix
- Liechtenstein · Idefirix
- Norway · Idefirix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c997036b-6124-4b20-9091-d42420e6e41a GET /v1/drugs/c997036b-6124-4b20-9091-d42420e6e41a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66170619",
"date_amm": "2020-08-25",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1471",
"substance": "IMLIFIDASE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about imlifidase.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.